An FDA Panel Just Endorsed These Unproven Peptides The recent vote by an FDA advisory committee to reclassify four popular peptides has left many in the medical community perplexed.
Proponents argue these substances are safer alternatives to illicit versions found on the grey market, but others warn approval could create new problems rather than solving old ones.
The rise of peptide therapies is a symptom of a growing disconnect between regulatory frameworks and popular wellness trends.